Figure 6 | Cell Discovery

Figure 6

From: Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA

Figure 6

Safety of TERT mRNA delivery to CD19 CAR T cells. (a) The karyotypes of CD19-CAR T cells were analyzed using conventional Giemsa staining and G-banding with trypsin and Giemsa (GTG) at 14 days after TERT mRNA delivery. A representative karyotype for one of the TERT-CD19-CAR T cells showed a normal 46, XY chromosome count with no abnormalities. (b) Karyotype analysis performed on overall TERT-CD19-CAR T cells revealed a normal karyotypes. (Untreated T cell: n=8, TERT-CD19-CAR-T: n=8). (c) The expression of cancer genes C-MYC, BMI1 and H-RAS, was detected by RT-qPCR relative to GAPDH at 7 and 14 days after TERT mRNA delivery. Untreated T cells (UN) were detected as control. (d) TERT-CD19-CAR T cells were subcutaneously injected into nude mice, and human Burkitt’s lymphoma Raji cells were subcutaneously injected as a positive control. Solid tumors formed after Raji cells were transplanted, and these mice remained alive for no more than 30 days and the mice in TERT-CD19-CAR T cell group were all in good condition.

Back to article page